Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Status:
Withdrawn
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard
treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National
Comprehensive Cancer Network guideline. However these recommendations were based on the
evidence in the two-dimensional conventional radiotherapy (2DCRT) era. The introduction of
intensity-modulated radiotherapy (IMRT) in NPC treatment has brought substantial better
treatment outcomes than 2DCRT. It has been questioned whether additional concurrent
chemotherapy is still necessary for intermediate risk NPC within the excellent framework of
IMRT. hus, we jointly conduct the first non-inferior randomized trial to determine the value
of concurrent chemotherapy with cisplatin for intermediate risk NPC patients treated with
IMRT. Given the results of clinical studies mentioned above, we decide to adopt the
concurrent regimen to be cisplatin 100 mg/m2 on day 1, 22, 43